Perspectives of SEREX-defined antigens in diagnosis and immunotherapy for gastric cancer

Cancer Biology and Therapy

Volumn 3, Issue 9, 2004, Pages 806-811

  Wang, Yunwei ^a   Gu, Qinlong ^a   Liu, Bingya ^a   Zhu, Zhenggang ^a  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

Author keywords

Antigen; Gastric cancer; Immunotherapy; SEREX; Vaccine

Indexed keywords

CANCER TESTIS ANTIGEN; COMPLEMENTARY DNA; DIFFERENTIATION ANTIGEN; FLUOROURACIL; RESISTIN; TUMOR ANTIGEN;

ANTIGEN PRESENTING CELL; CANCER DIAGNOSIS; CANCER SCREENING; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CPG ISLAND; CYTOTOXIC T LYMPHOCYTE; DNA LIBRARY; DNA SEQUENCE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENE MAPPING; GENE MUTATION; GENE TARGETING; HISTOCOMPATIBILITY COMPLEX; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; IMMUNOTHERAPY; MELANOMA; NONHUMAN; RETROVIRUS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SEROLOGY; STOMACH CANCER; TRANSGENE; TUMOR GROWTH; TUMOR IMMUNITY; VACCINATION; DIFFERENTIAL DIAGNOSIS; GENE LIBRARY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; STOMACH TUMOR;

ANTIGENS, NEOPLASM; DIAGNOSIS, DIFFERENTIAL; GENE LIBRARY; HIV SEROPOSITIVITY; HUMANS; IMMUNOTHERAPY; SEROLOGIC TESTS; SEROLOGY; STOMACH NEOPLASMS;

EID: 18744402498     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.3.9.1140     Document Type: Review

References (51)

1. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA: Cancer J Clin 2002; 52:23-47.
2. Hundahl SA, Phillips JL, Menck HR. The national cancer data base report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy. 5th ed. American joint committee on cancer staging, proximal disease, and the "different disease" hypothesis. Cancer 2000; 88:921-32.
3. Shimada K, Ajani JA. Adjuvant therapy for gastric carcinoma patients in the past 15 years: A review of western and oriental trials. Cancer 1999; 86:1657-68.
4. Yao JC, Ajani JA. Adjuvant and preoperative chemotherapy for gastric cancer. Curr Oncol Rep 2002; 4:222-8.
5. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature 2001; 411:380-4.
6. Marchand M, van Baren N, Weynants P, Brichard V, Dreno B, Tessier MH, et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 1999; 80:219-30.
7. Lissoni P, Brivio F, Ardizzoia A, Tancini G, Barni S. Subcutaneous therapy with low-dose interleukin-2 plus the neurohormone melatonin in metastatic gastric cancer patients with low performance status. Clin Tumori 1993; 79:401-4.
8. Lissoni P, Barni S, Ardizzoia A, Olivini G, Brivio F, Tisi E, et al. Cancer immunotherapy with low-dose interleukin-2 subcutaneous administration: Potential efficacy in most solid tumor histotypes by a concomitant treatment with the pineal hormone melatonin. J Biol Regul Homeost Agents 1993; 7:121-5.
9. Kono K, Rongcun Y, Charo J, Ichihara F, Celis E, Sette A, et al. Identification of HER2/neu-derived peptide epitopes recognized by gastric cancer-specific cytotoxic T lymphocytes. Int J Cancer 1998; 78:202-8.
10. Nguyen T, Naziruddin B, Dintzis S, Doherty GM, Mohanakumar T. Recognition of breast cancer-associated peptides by tumor-reactive, HLA-class I restricted allogeneic cytotoxic T lymphocytes. Int J Cancer 1999; 81:607-15.
11. Dudley ME, Ngo LT, Westwood J, Wunderlich JR, Rosenberg SA. T-cell clones from melanoma patients immunized against an anchor-modified gp100 peptide display discordant effector phenotypes. Cancer J 2000; 6:69-77.
12. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298:850-4.
13. Engleman EG. Dendritic cell-based cancer immunotherapy. Semin Oncol 2003; 30:23-9.
14. Sahin U, Tureci O, Schmitt H, Cochlovius B, Johannes T, Schmits R, et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA 1995; 92:11810-3.
15. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254:1643-7.
16. Old LJ, Chen YT. New paths in human cancer serology. J Exp Med 1998; 187:1163-7.
17. Thurner B, Haendle I, Roder C, Dieckmann D, Keikavoussi P, Jonuleit H, et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 1999; 190:1669-78.
18. Jager E, Gnjatic S, Nagata Y, Stockert E, Jager D, Karbach J, et al. Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc Natl Acad Sci USA 2000; 97:12198-203.
19. Tajima K, Obata Y, Tamaki H, Yoshida M, Chen YT, Scanlan MJ, et al. Expression of cancer/testis (CT) antigens in lung cancer. Lung Cancer 2003; 42:23-33.
20. Cho B, Lim Y, Lee DY, Park SY, Lee H, Kim WH, et al. Identification and characterization of a novel cancer/testis antigen gene CAGE. Biochem Biophys Res Commun 2002; 292:715-26.
21. Cho B, Lee H, Jeong S, Bang YJ, Lee HJ, Hwang KS, et al. Promoter hypomethylation of a novel cancer/testis antigen gene CAGE is correlated with its aberrant expression and is seen in premalignant stage of gastric carcinoma. Biochem Biophys Res Commun 2003; 307:52-63.
22. Line A, Stengrevics A, Slucka Z, Li G, Jankevics E, Rees RC. Serological identification and expression analysis of gastric cancer-associated genes. Br J Cancer 2002; 86:1824-30.
23. Line A, Slucka Z, Stengrevics A, Li G, Rees RC. Altered splicing pattern of TACC1 mRNA in gastric cancer. Cancer Genet Cytogenet 2002; 139:78-83.
24. Sazani P, Kole R. Therapeutic potential of antisense oligonucleotides as modulators of alternative splicing. J Clin Invest 2003; 112:481-6.
25. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991; 253:49-53.
26. Yamada Y, Yoshida T, Hayashi K, Sekiya T, Yokota J, Hirohashi S, et al. p53 gene mutations in gastric cancer metastases and in gastric cancer cell lines derived from metastases. Cancer Res 1991; 51:5800-5.
27. Correa P, Shiao YH. Phenotypic and genotypic events in gastric carcinogenesis. Phenotypic and genotypic events in gastric carcinogenesis. Cancer Res 1994; 54:1941s-3s.
28. Umano Y, Tsunoda T, Tanaka H, Matsuda K, Yamaue H, Tanimura H. Generation of cytotoxic T cell responses to an HLA-A24 restricted epitope peptide derived from wild-type p53. Br J Cancer 2001; 84:1052-7.
29. Wurtzen PA, Pedersen LO, Poulsen HS, Claesson MH. Specific killing of p53 mutated tumor cell lines by a cross-reactive human HLA-A2-restricted P53-specific CTL line. Int J Cancer 2001; 93:855-61.
30. Azuma K, Shichijo S, Maeda Y, Nakatsura T, Nonaka Y, Fujii T, et al. Mutated p53 gene encodes a nonmutated epitope recognized by HLA-B*4601- restricted and tumor cell-reactive CTLs at tumor site. Cancer Res 2003; 63:854-8.
31. Noguchi Y, Richards EC, Chen YT, Old LJ. Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma. Proc Natl Acad Sci USA 1995; 92:2219-23.
32. Scanlan MJ, Gordan JD, Williamson B, Stockert E, Bander NH, Jongeneel V, et al. Antigens recognized by autologous antibody in patients with renal-cell carcinoma. Int J Cancer 1999; 83:456-64.
33. Scanlan MJ, Welt S, Gordon CM, Chen YT, Gure AO, Stockert E, et al. Cancer-related serological recognition of human colon cancer: Identification of potential diagnostic and immunotherapeutic targets. Cancer Res 2002; 62:4041-7.
34. Krause P, Tureci O, Micke P, Buhl R, Huber C, Sahin U. SeroGRID: An improved method for the rapid selection of antigens with disease related immunogenicity. J Immunol Methods 2003; 283:261-7.
35. Lagarkova MA, Koroleva EP, Kuprash DV, Boitchenko VE, Kashkarova UA, Nedospasov SA, et al. Evaluation of humoral response to tumor antigens using recombinant expression-based serological mini-arrays (SMARTA). Immunol Lett 2003; 85:71-4.
36. Marchand M, van Baren N, Weynants P, Brichard V, Dreno B, Tessier MH, et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 1999; 80:219-30.
37. Kono K, Rongcun Y, Charo J, Ichihara F, Celis E, Sette A, et al. Identification of HER2/neu-derived peptide epitopes recognized by gastric cancer-specific cytotoxic T lymphocytes. Int J Cancer 1998; 78:202-8.
38. + gastric cancer patients by in vitro stimulation with antigenic peptide of signet ring cell carcinoma. Jpn J Cancer Res 2000; 91:616-21.
39. Fujie T, Tanaka F, Tahara K, Li J, Tanaka S, Mori M, et al. Generation of specific antitumor reactivity by the stimulation of spleen cells from gastric cancer patients with MAGE-3 synthetic peptide. Cancer Immunol Immunother 1999; 48:189-94.
40. Sasada T, Takedatsu H, Azuma K, Koga M, Maeda Y, Shichijo S, et al. Immediate early response gene X-1, a stress-inducible antiapoptotic gene, encodes cytotoxic T-lymphocyte (CTL) epitopes capable of inducing human leukocyte antigen-A33-restricted and tumor-reactive CTLs in gastric cancer patients. Cancer Res 2004; 64:2882-8.
41. Johnen H, Kulbe H, Pecher G. Long-term tumor growth suppression in mice immunized with naked DNA of the human tumor antigen mucin (MUC1). Cancer Immunol Immunother 2001; 50:356-60.
42. Kanai F, Kawakami T, Hamada H, Sadata A, Yoshida Y, Tanaka T, et al. Adenovirus-mediated transduction of Escherichia coli uracil phosphoribosyltransferase gene sensitizes cancer cells to low concentrations of 5-fluorouracil. Cancer Res 1998; 58:1946-51.
43. Gong J, Nikrui N, Chen D, Koido S, Wu Z, Tanaka Y, et al. Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity. J Immunol 2000; 165:1705-11.
44. Sadanaga N, Nagashima H, Mashino K, Tahara K, Yamaguchi H, Ohta M, et al. Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas. Clin Cancer Res 2001; 7:2277-84.
45. Kono K, Takahashi A, Sugai H, Fujii H, Choudhury AR, Kiessling R, et al. Dendritic cells pulsed with HER-2/neu-derived peptides can induce specific T-cell responses in patients with gastric cancer. Clin Cancer Res 2002; 8:3394-400.
46. Li G, Miles A, Line A, Rees RC. Identification of tumour antigens by serological analysis of cDNA expression cloning. Cancer Immunol Immunother 2004; 53:139-43.
47. Kim YM, Lee YH, Shin SH, Kim EH, Choi YW, Lee KM, et al. Expression of MAGE-1, -2, and -3 genes in gastric carcinomas and cancer cell lines derived from Korean patients. J Korean Med Sci 2001; 16:62-8.
48. Mashino K, Sadanaga N, Tanaka F, Yamaguchi H, Nagashima H, Inoue H, et al. Expression of multiple cancer-testis antigen genes in gastrointestinal and breast carcinomas. Br J Cancer 2001; 85:713-20.
49. Wang JY, Lin SR, Hsieh JS, Hsu CH, Huang YS, Huang TJ. Mutations of p53 gene in gastric carcinoma in Taiwan. Anticancer Res 2001; 21:513-20.
50. Obata Y, Takahashi T, Sakamoto J, Tamaki H, Tominaga S, Hamajima N, et al. SEREX analysis of gastric cancer antigens. Cancer Chemother Pharmacol 2000; 46:S37-42.
51. Ishikawa T, Kobayashi M, Mai M, Suzuki T, Ooi A. Amplification of the c-erbB-2 (HER-2/neu) gene in gastric cancer cells. Detection by fluorescence in situ hybridization. Am J Pathol 1997; 151:761-8.